The Association between GABA-Modulators and Clostridium difficile Infection – A Matched Retrospective Case-Control Study
Open Access
- 6 January 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1) , e0169386
Abstract
Recently, metabolomics studies have suggested that the neurotransmitter γ-amino butyric acid (GABA) may modulate C. difficile infection (CDI) pathogenesis. In the present study, we investigated the association between GABA-modulating pharmaceuticals and CDI development. In July-December 2013, we performed a matched, retrospective case-control study in Skåne county, Sweden, to assess the association between the use of GABA-modulators (defined as regular use of at least one of the following: zolpidem, zopiclone, benzodiazepines, gabapentin, pregabalin or baclofen) and CDI. Multivariate regression models, adjusted for known risk factors for CDI, were fitted to assess the associations and a propensity score-adjusted analysis was performed. The study included 292 cases and 292 matched controls. In a multivariate regression model only recent antibiotic use (clindamycin, cephalosporins and fluoroquinolones) and nursing home residency was significantly associated with CDI. The regular use of any GABA-modulator was not associated with CDI (OR = 1.07, 95%CI 0.69–1.66, p = 0.76). The association between regular use of the selective GABA-agonist zolpidem and CDI trended towards significance (OR = 2.31, 95%CI 0.91–5.86, p = 0.078). These associations remained when only cases treated with antibiotics were included. Corresponding findings for zolpidem was observed in a propensity-score adjusted analysis (OR = 2.52, 95% CI 0.91–6.97, p = 0.075). Severe initial CDI was significantly associated with CDI recurrence (OR = 3.77, 95% CU 1.20–11.86, p = 0.023). This study did not identify a general association between GABA-modulators and CDI. A trend towards a significant association between zolpidem and CDI was observed, an association that should be re-assessed in a study appropriately powered for this particular hypothesis.Keywords
This publication has 29 references indexed in Scilit:
- Depression, antidepressant medications, and risk of Clostridium difficileinfectionBMC Medicine, 2013
- Current Status of Clostridium difficile Infection EpidemiologyClinical Infectious Diseases, 2012
- Statin use and the risk of Clostridium difficile in academic medical centresGut, 2012
- Update on Clostridium difficile infectionCurrent Opinion in Gastroenterology, 2011
- Inhibitory role for GABA in autoimmune inflammationProceedings of the National Academy of Sciences, 2010
- Risk Factors for and Estimated Incidence of Community-associatedClostridium difficileInfection, North Carolina, USA1Emerging Infectious Diseases, 2010
- Purposeful selection of variables in logistic regressionSource Code for Biology and Medicine, 2008
- Increase in AdultClostridium difficile–related Hospitalizations and Case-Fatality Rate, United States, 2000–2005Emerging Infectious Diseases, 2008
- Increase inClostridium difficile–related Mortality Rates, United States, 1999–2004Emerging Infectious Diseases, 2007
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987